Last I saw the RCTs in kids at this age failed to meet the modest benchmark of non-inferior antibody titers from 2 doses of 3 micrograms of vax. Pfizer had extended the trial to add a 3rd dose, but the trial is ongoing. What changed? Do we realize how low a bar this is? π§΅
https://twitter.com/disclosetv/status/1488318361041838080
We are going to approve mass vaccination in the USA based on antibody levels-- not fewer severe cases of COVID19. The trial has absolutely no power to ascertain this rare outcome in kids.
But, even that low bar was not met. the trial added a 3rd dose as Ab levels low
But, even that low bar was not met. the trial added a 3rd dose as Ab levels low
So has the trial met the endpoint?
Is this really the evidence we want? Or should we demand more
Our failure was not demanding kids RCT powered for clinical endpoints.
Is this really the evidence we want? Or should we demand more
Our failure was not demanding kids RCT powered for clinical endpoints.
Finally, let's remember that not all nations view this the same
reuters.com/world/europe/sβ¦
reuters.com/world/europe/sβ¦
β’ β’ β’
Missing some Tweet in this thread? You can try to
force a refresh
γ
